Skip to main content

Table 4 Prior chemotherapy agents before EGFR and FGFR inhibitor therapy in affected patients

From: Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors

 CaseDrugSexAgeDiagnosisPrior chemotherapy agents before study drugs
EGFR inhibitor (Tyrosine Kinase Inhibitor)1Vandetanib230–39NSCLCDoxorubicin, Cisplatin, Pemetrexed, Geftinib, Gemcitabine
2260–69NSCLCDoxorubicin, cisplatin
3270–79NSCLCGemcitabine, cisplatin
4Osimertinib250–59NSCLCAfatinib
5ABT-414150–59GlioblastomaTemozolomide
6270–79GlioblastomaTemozolomide
7250–59GlioblastomaTemozolomide
8140–49GlioblastomaTemozolomide
9260–69Glioblastomanone
FGFR inhibitor10ASP5878240–49HCCSorafenib, Ramucirumab, Everolimus
11FPA144240–49Gastric cancerCapecitabine, Oxaliplatin, Paclitaxel, Doxorubicin, Cisplatin, Irinotecan
12260–69Gastric cancerGemcitabine, Cisplatin, Doxorubicin, Capecitabine, Oxaliplatin
  1. EGFR epidermal growth factor receptor, FGFR fibroblast growth factor receptor, NSCLC Non-small cell lung cancer, HCC Hepatocellular carcinoma
\